Carpal Tunnel Release Effects on Median Nerve Perfusion
NCT ID: NCT01610739
Last Updated: 2019-08-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2012-07-31
2013-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Perineural Injection Therapy in Patients With Carpal Tunnel Syndrome
NCT02809261
Refining the Interpretation of the Tinel's Sign for Carpal Tunnel Syndrome
NCT05969093
The Dose Effect of Extracorporeal Shock Wave Therapy in Patients With Carpal Tunnel Syndrome
NCT02800187
Corticosteroid Injection Effectiveness in Carpel Tunnel Patients With Negative or Mild EMG Studies
NCT04737239
The Effect of Hydrodissection for Carpal Tunnel Syndrome
NCT02991001
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Median nerve perfusion
Injection of indigocyanine green dye to evaluate perfusion of the median nerve with the SPY scope before and after carpal tunnel release
Indigocyanine green dye
Each patient will receive 1 injection of indigocyanine green dye using 2.5 mg/mL concentration of the imaging agent. 3mL of this mixture will be injected intravenously, followed by 10mL NS bolus, just prior to imaging with the SPY scope
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Indigocyanine green dye
Each patient will receive 1 injection of indigocyanine green dye using 2.5 mg/mL concentration of the imaging agent. 3mL of this mixture will be injected intravenously, followed by 10mL NS bolus, just prior to imaging with the SPY scope
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18 years or older
Exclusion Criteria
* less than 18 years of age
* allergy to iodide or iodinated contrast agents
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Henry Ford Health System
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nadia M. Obeid, MD
M.D.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nadia M Obeid, MD
Role: PRINCIPAL_INVESTIGATOR
Henry Ford Health System
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Henry Ford Hospital
Detroit, Michigan, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HFHSobeid2012
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.